• Regimens, Medicines, and Physiotherapy

  Ensifentrine for Cystic Fibrosis Enters Phase 2 Trial

  Posted by cystic-fibrosis-news-moderator on January 16, 2019 at 9:22 am

  The World Health Organization has given RPL554 the identifying name ensifentrine. Ensifentrine is a potential inhaled therapy for cystic fibrosis developed by Verona Pharma, and it is now in a Phase 2 clinical trial. Click here to learn more about it.

  Are you interested in following news about this potential therapy for CF?

  cystic-fibrosis-news-moderator replied 5 years, 3 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply